Results 211 to 220 of about 239,234 (339)

Interference against a newly labeled substance with ruthenium sulfonate complexes showing discrepant thyroid function test results

, 2023
Sawako Takahashi, Mitsushige Nishikawa, Eijun Nishihara, Hanna Deguchi, Kazuyoshi Kohsaka, Hiroyuki Yamaoka, Mako Hisakado, Shuji Fukata, Ito M, Akira Miyauchi, Takashi Akamizu   +10 more
openalex   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Wide Spectrum of Thyroid Function Tests in COVID-19: From Nonthyroidal Illness to Isolated Hyperthyroxinemia. [PDF]

Int J Endocrinol Metab, 2022
Hashemipour S, Shahsavari P, Kiani S, Badri M, Ghobadi A, Hadizadeh Khairkhahan SMR, Tariverdi A.   +6 more
europepmc   +1 more source

Cytomorphological Evaluation And Thyroid Function Test (Tft) Analysis In Various Thyroid Diseases “Our Experience At Tertiary Care Centre”

, 2014
Junu Devi, Naima Aziz
openalex   +1 more source

Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms

British Journal of Clinical Pharmacology, EarlyView.
Aim To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. Methods This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies ...
Sílvia M. Illamola, Zachary N. Stowe, Marc L. Kalin, Michael D. Evans, Catherine M. Sherwin, Maged M. Costantine, D. Jeffrey Newport, James C. Ritchie, Angela K. Birnbaum   +8 more
wiley   +1 more source

Thyroid function tests and serum anti-Müllerian hormone in various populations, is there any association? A systematic review and meta-analysis. [PDF]

Arch Gynecol Obstet
Amani-Beni R, Darouei B, Ghadimi Nooran S, Karimi Shervedani A, Kakavand N, Amini-Salehi E, Hashemi SM, Rabiee Rad M, Ghasempour Dabaghi G, Heidarpour M.   +9 more
europepmc   +1 more source

Variable Diagnoses in Cases Referred for Discordant Thyroid Function Tests: Focus on Lymphoproliferative Disorders

Antonio Musolino, Gino Grifoni, Simone Rodolfi, Massimiliano Andreasi, Ilaria Bulgarelli, Flaminia Fanelli, Valentina Morelli, Luca Persani, Irene Campi   +8 more
openalex   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Relationship Between Thyroid Function Tests and Birth Parameters at 41-Week-And-Above Pregnancies: A Prospective Cohort Study. [PDF]

Diagnostics (Basel)
Sivas MC, Ohanoglu Cetinel K, Geyikoglu IE.   +2 more
europepmc   +1 more source

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat

British Journal of Clinical Pharmacology, EarlyView.
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
Annemieke M. Peters van Ton, Nielka P. van Erp, Annenienke C. van de Ven, Janneke E. W. Walraven, Loek A. W. de Jong   +4 more
wiley   +1 more source